metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española PET- FDG en cáncer oculto primario de mama
Información de la revista
Vol. 70. Núm. 2.
Páginas 105-107 (agosto 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 70. Núm. 2.
Páginas 105-107 (agosto 2001)
Acceso a texto completo
PET- FDG en cáncer oculto primario de mama
Positron Emission Tomography with Fluorine-18-Fluorodeoxyglucose in occult primary breast carcinoma
Visitas
9809
G. Ruiz
A. Jiménez*, M.J. Pérez*, R. Montz*, M. González**, J.L. Carreras*,***,1
* Instituto PET Dr. Carreras. Madrid.
** Servicio de Oncología Médica. Hospital Universitario la Paz. Madrid.
*** Servicio de Medicina Nuclear. Hospital Clínico Universitario San Carlos. Madrid.
Este artículo ha recibido
Información del artículo
Resumen

La tomografía por emisión de positrones es una técnica de eficacia comprobada en la detección de la afección locoregional y a distancia del cáncer de mama.

Presentamos el caso de dos pacientes con afección axilar secundaria a cáncer oculto de mama, en los que la tomografía por emisión de positrones con 18-fluoro-2-desoxi-D-glucosa (PET-FDG) permitió identificar la localización del tumor primario y por tanto efectuar un tratamiento quirúrgico posterior.

Analizamos, además, la utilidad de la PET-FDG y de los métodos de imagen convencionales en el diagnóstico de esta entidad.

Palabras clave:
Carcinoma primario oculto de mama
Tomografía de emisión por positrones (PET)
18-fluoro-2- desoxi-D-glucosa (FDG)

Positron emission tomography (PET) has been proved to be effective in detecting locoregional and distant breast cancer. We report two patients with axillary involvement secondary to occult primary breast carcinoma. The use of PET with fluorine-18-fluorodeoxyglucose (FDG) enabled identification of the primary breast tumor and the appropriate surgical treatment to be given. In addition, we analyze the usefulness of PET-FDG and that of conventional imaging methods in the diagnosis of this entity.

Key words:
Occult primary breast cancer
Positron emission tomography (PET)
18-fluoro-2-deoxy-D-glucose (FDG)
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Merson, S. Andreoia, V. Galimberti, R. Bufalino, S. Marchini, et al.
Breast carcinoma presenting as axillary metastases without evidence of a primary tumor.
Cancer, 70 (1992), pp. 504-508
[2.]
B. Van Ooijen, M. Bontenbal, S.C. Henzen-Logmans, P.C. Koper.
Axillary nodal metastases from an occult primary consistent with breast carcinoma.
Br J Surg, 80 (1993), pp. 1299-1300
[3.]
G.H. Sakarofas, A.G. Tsiotou.
Occult breast cancer: a challenge from a surgical perspective.
Surg Oncol, 8 (1999), pp. 27-33
[4.]
W.S. Halsted.
The results of radical operations for the cure of carcinoma of the breast.
Ann Surg, 46 (1907), pp. 1-19
[5.]
P. Rigo, P. Paulus, B.J. Kaschten, R. Hustinx, T. Bury, G. Jerusalem, et al.
Oncological applications of positron emission tomography with fluorine-18 florodeoxyglucose.
Eur J Nucl Med, 23 (1996), pp. 1641-1674
[6.]
N.Y. Tse, C.K. Hoh, R.A. Hawkins, M.J. Zinner, M. Dahlbom, Y. Choi, et al.
The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease.
Ann Surg, 216 (1992), pp. 27-34
[7.]
E.F. Block, M.A. Meyer.
Positron emission tomography in diagnosis of occult adenocarcinoma of the breast.
Am Surg, 64 (1998), pp. 906-908
[8.]
C.R. Scoggins, J.V. Vitola, M.P. Sandler, J.B. Atkinson, M. Frexes-Steed.
Occult breast carcinoma presenting as an axillary mass.
Am Surg, 65 (1999), pp. 1-5
[9.]
V.P. Jackson.
What is the role of sonographic breast imaging for detecting occult cancer in a patient with a strong family history of breast cancer and mammographically dense breasts without obvious masses?.
AJR Am J Roentgenol, 165 (1995), pp. 1004
[10.]
V.P. Jackson.
The role of US in breast imaging.
Radiology, 177 (1990), pp. 305-311
[11.]
Kopans DB. “Early” breast cancer detection using techniques other than mammography. AJR Am J Radiol 198; 143: 465-468
[12.]
P.J. Sianetz, R. Jain, J.L. Kline, K.A. McCarthy, J.L. Goldenberg, W.B. Edmister.
CT-guided preoperative needle localization of MR imagingdetected mammographically occult lesions.
AJR Am J Roentgenol, 172 (1999), pp. 160-162
[13.]
S. Greenstein, M. Schnall, V. LiVolsi, R. Troupin.
Suspicious breast lesions: MR imaging with radiologic- pathologic correlation.
Radiology, 190 (1994), pp. 485-493
[14.]
P. Stomper, S. Herman, D. Klippenstein, J. Winston, S. Edge, M. Arredondo, et al.
Suspect breast lesions: findings at dynamic gadoliniumenhanced MR imaging correlated with mammmographic and pathologic features.
Radiology, 197 (1995), pp. 387-395
[15.]
S.G. Orel, M.G. Hochman, M.D. Schnall, C. Reynolds, D.C. Sullivan.
High-resolution MR imaging of the breast: clinical context.
Radiographics, 16 (1996), pp. 1385-1401
[16.]
E. Morris, L. Schwartz, D. Dershaw, K. Van Zee, A. Abramson, L. Liberman, et al.
MR imaging of the breast in patients with occult primary breast carcinoma.
Radiology, 205 (1997), pp. 437-440
[17.]
N. Avril, C. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, et al.
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
J Clin Oncol, 18 (2000), pp. 3495-3502
Copyright © 2001. Asociación Española de Cirujanos
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos